10x Genomics (TXG) Competitors

10x Genomics logo
$51.70 -5.68 (-9.90%)
Closing price 03:58 PM Eastern
Extended Trading
$52.36 +0.66 (+1.28%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

TXG vs. ILMN, PACB, TWST, MTD, and MEDP

Should you buy 10x Genomics stock or one of its competitors? 10x Genomics's main competitors and comparable companies include Illumina (ILMN), Pacific Biosciences of California (PACB), Twist Bioscience (TWST), Mettler-Toledo International (MTD), and Medpace (MEDP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does 10x Genomics compare to Illumina?

10x Genomics (NASDAQ:TXG) and Illumina (NASDAQ:ILMN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

Illumina has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
10x Genomics$642.82M11.74-$43.54M-$0.52N/A
Illumina$4.34B6.99$850M$5.8134.54

10x Genomics presently has a consensus price target of $68.40, indicating a potential upside of 19.21%. Illumina has a consensus price target of $243.72, indicating a potential upside of 21.47%. Given Illumina's stronger consensus rating and higher possible upside, analysts plainly believe Illumina is more favorable than 10x Genomics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
10x Genomics
1 Sell rating(s)
12 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.22
Illumina
3 Sell rating(s)
8 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.30

Illumina has a net margin of 19.72% compared to 10x Genomics' net margin of -10.84%. Illumina's return on equity of 28.38% beat 10x Genomics' return on equity.

Company Net Margins Return on Equity Return on Assets
10x Genomics-10.84% -8.19% -6.46%
Illumina 19.72%28.38%12.11%

10x Genomics has a beta of 2.03, meaning that its stock price is 103% more volatile than the broader market. Comparatively, Illumina has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market.

84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 89.4% of Illumina shares are owned by institutional investors. 8.8% of 10x Genomics shares are owned by insiders. Comparatively, 2.9% of Illumina shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Illumina had 7 more articles in the media than 10x Genomics. MarketBeat recorded 17 mentions for Illumina and 10 mentions for 10x Genomics. Illumina's average media sentiment score of 0.71 beat 10x Genomics' score of 0.57 indicating that Illumina is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
10x Genomics
4 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Illumina
11 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Illumina beats 10x Genomics on 13 of the 16 factors compared between the two stocks.

How does 10x Genomics compare to Pacific Biosciences of California?

Pacific Biosciences of California (NASDAQ:PACB) and 10x Genomics (NASDAQ:TXG) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

10x Genomics has higher revenue and earnings than Pacific Biosciences of California. 10x Genomics is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pacific Biosciences of California$160.01M3.44-$546.38M-$0.42N/A
10x Genomics$642.82M11.74-$43.54M-$0.52N/A

10x Genomics has a net margin of -10.84% compared to Pacific Biosciences of California's net margin of -81.31%. 10x Genomics' return on equity of -8.19% beat Pacific Biosciences of California's return on equity.

Company Net Margins Return on Equity Return on Assets
Pacific Biosciences of California-81.31% -5,752.12% -19.52%
10x Genomics -10.84%-8.19%-6.46%

Pacific Biosciences of California has a beta of 2.21, meaning that its stock price is 121% more volatile than the broader market. Comparatively, 10x Genomics has a beta of 2.03, meaning that its stock price is 103% more volatile than the broader market.

In the previous week, 10x Genomics had 5 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 10 mentions for 10x Genomics and 5 mentions for Pacific Biosciences of California. Pacific Biosciences of California's average media sentiment score of 0.88 beat 10x Genomics' score of 0.57 indicating that Pacific Biosciences of California is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pacific Biosciences of California
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
10x Genomics
4 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Pacific Biosciences of California presently has a consensus target price of $2.57, suggesting a potential upside of 45.83%. 10x Genomics has a consensus target price of $68.40, suggesting a potential upside of 19.21%. Given Pacific Biosciences of California's higher possible upside, analysts clearly believe Pacific Biosciences of California is more favorable than 10x Genomics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pacific Biosciences of California
2 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.60
10x Genomics
1 Sell rating(s)
12 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.22

84.7% of 10x Genomics shares are held by institutional investors. 3.7% of Pacific Biosciences of California shares are held by insiders. Comparatively, 8.8% of 10x Genomics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

10x Genomics beats Pacific Biosciences of California on 11 of the 16 factors compared between the two stocks.

How does 10x Genomics compare to Twist Bioscience?

Twist Bioscience (NASDAQ:TWST) and 10x Genomics (NASDAQ:TXG) are both mid-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

10x Genomics has a net margin of -10.84% compared to Twist Bioscience's net margin of -28.34%. 10x Genomics' return on equity of -8.19% beat Twist Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Twist Bioscience-28.34% -22.18% -16.02%
10x Genomics -10.84%-8.19%-6.46%

In the previous week, Twist Bioscience had 12 more articles in the media than 10x Genomics. MarketBeat recorded 22 mentions for Twist Bioscience and 10 mentions for 10x Genomics. 10x Genomics' average media sentiment score of 0.57 beat Twist Bioscience's score of 0.23 indicating that 10x Genomics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Twist Bioscience
4 Very Positive mention(s)
5 Positive mention(s)
5 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral
10x Genomics
4 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

10x Genomics has higher revenue and earnings than Twist Bioscience. 10x Genomics is trading at a lower price-to-earnings ratio than Twist Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Twist Bioscience$459.43M15.24-$130.20M-$2.09N/A
10x Genomics$642.82M11.74-$43.54M-$0.52N/A

84.7% of 10x Genomics shares are held by institutional investors. 3.1% of Twist Bioscience shares are held by company insiders. Comparatively, 8.8% of 10x Genomics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Twist Bioscience presently has a consensus price target of $133.92, suggesting a potential upside of 19.98%. 10x Genomics has a consensus price target of $68.40, suggesting a potential upside of 19.21%. Given Twist Bioscience's stronger consensus rating and higher possible upside, equities research analysts clearly believe Twist Bioscience is more favorable than 10x Genomics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Twist Bioscience
2 Sell rating(s)
3 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.42
10x Genomics
1 Sell rating(s)
12 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.22

Twist Bioscience has a beta of 2.25, indicating that its stock price is 125% more volatile than the broader market. Comparatively, 10x Genomics has a beta of 2.03, indicating that its stock price is 103% more volatile than the broader market.

Summary

10x Genomics beats Twist Bioscience on 9 of the 16 factors compared between the two stocks.

How does 10x Genomics compare to Mettler-Toledo International?

10x Genomics (NASDAQ:TXG) and Mettler-Toledo International (NYSE:MTD) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

In the previous week, 10x Genomics had 7 more articles in the media than Mettler-Toledo International. MarketBeat recorded 10 mentions for 10x Genomics and 3 mentions for Mettler-Toledo International. Mettler-Toledo International's average media sentiment score of 0.95 beat 10x Genomics' score of 0.57 indicating that Mettler-Toledo International is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
10x Genomics
4 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Mettler-Toledo International
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

10x Genomics has a beta of 2.03, meaning that its stock price is 103% more volatile than the broader market. Comparatively, Mettler-Toledo International has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market.

Mettler-Toledo International has a net margin of 22.25% compared to 10x Genomics' net margin of -10.84%. Mettler-Toledo International's return on equity of 15,012.71% beat 10x Genomics' return on equity.

Company Net Margins Return on Equity Return on Assets
10x Genomics-10.84% -8.19% -6.46%
Mettler-Toledo International 22.25%15,012.71%25.41%

Mettler-Toledo International has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
10x Genomics$642.82M11.74-$43.54M-$0.52N/A
Mettler-Toledo International$4.03B8.42$869.19M$46.1536.95

84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 95.1% of Mettler-Toledo International shares are owned by institutional investors. 8.8% of 10x Genomics shares are owned by company insiders. Comparatively, 0.7% of Mettler-Toledo International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

10x Genomics presently has a consensus target price of $68.40, indicating a potential upside of 19.21%. Mettler-Toledo International has a consensus target price of $1,595.77, indicating a potential downside of 6.41%. Given 10x Genomics' higher probable upside, equities research analysts clearly believe 10x Genomics is more favorable than Mettler-Toledo International.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
10x Genomics
1 Sell rating(s)
12 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.22
Mettler-Toledo International
1 Sell rating(s)
8 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.33

Summary

Mettler-Toledo International beats 10x Genomics on 11 of the 16 factors compared between the two stocks.

How does 10x Genomics compare to Medpace?

10x Genomics (NASDAQ:TXG) and Medpace (NASDAQ:MEDP) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 78.0% of Medpace shares are held by institutional investors. 8.8% of 10x Genomics shares are held by insiders. Comparatively, 20.5% of Medpace shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

10x Genomics has a beta of 2.03, meaning that its share price is 103% more volatile than the broader market. Comparatively, Medpace has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

In the previous week, 10x Genomics had 5 more articles in the media than Medpace. MarketBeat recorded 10 mentions for 10x Genomics and 5 mentions for Medpace. Medpace's average media sentiment score of 0.94 beat 10x Genomics' score of 0.57 indicating that Medpace is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
10x Genomics
4 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Medpace
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

10x Genomics presently has a consensus price target of $68.40, suggesting a potential upside of 19.21%. Medpace has a consensus price target of $649.27, suggesting a potential upside of 2.41%. Given 10x Genomics' higher probable upside, analysts plainly believe 10x Genomics is more favorable than Medpace.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
10x Genomics
1 Sell rating(s)
12 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.22
Medpace
0 Sell rating(s)
10 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.23

Medpace has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
10x Genomics$642.82M11.74-$43.54M-$0.52N/A
Medpace$2.53B7.01$451.12M$18.0435.14

Medpace has a net margin of 18.24% compared to 10x Genomics' net margin of -10.84%. Medpace's return on equity of 99.76% beat 10x Genomics' return on equity.

Company Net Margins Return on Equity Return on Assets
10x Genomics-10.84% -8.19% -6.46%
Medpace 18.24%99.76%24.47%

Summary

Medpace beats 10x Genomics on 10 of the 16 factors compared between the two stocks.

Get 10x Genomics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TXG and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TXG vs. The Competition

Metric10x GenomicsLife Sciences Tools & Services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$7.23B$10.69B$7.77B$11.72B
Dividend YieldN/A1.46%2.47%4.72%
P/E Ratio-99.4246.2331.9826.62
Price / Sales10.588.468.105.42
Price / CashN/A26.5521.0121.90
Price / Book8.124.194.263.50
Net Income-$43.54M$56.66B$3.50B$394.12M
7 Day Performance-11.16%-6.04%-7.93%-8.92%
1 Month Performance-27.66%-6.86%-10.46%-12.02%
1 Year Performance214.08%16.24%-2.79%-9.62%

10x Genomics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TXG
10x Genomics
3.084 of 5 stars
$51.70
-9.9%
$68.40
+32.3%
+266.6%$7.23B$642.82MN/A1,178
ILMN
Illumina
3.6557 of 5 stars
$220.78
+3.6%
$244.24
+10.6%
+67.0%$34.25B$4.34B43.158,650
PACB
Pacific Biosciences of California
2.1502 of 5 stars
$2.36
+4.4%
$2.43
+2.8%
+0.0%$792.62M$160.01MN/A485
TWST
Twist Bioscience
2.8209 of 5 stars
$135.34
+12.0%
$153.00
+13.0%
+338.6%$8.94B$376.57MN/A979
MTD
Mettler-Toledo International
2.5938 of 5 stars
$1,762.04
+2.3%
$1,595.77
-9.4%
+21.4%$34.53B$4.03B38.4018,100

Related Companies and Tools


This page (NASDAQ:TXG) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners